종양학용 바이오시밀러 시장 : 용도별, 최종사용자별 - 세계 예측(2025-2030년)

The Oncology Biosimilars Market was valued at USD 4.65 billion in 2023, expected to reach USD 5.48 billion in 2024, and is projected to grow at a CAGR of 18.11%, to USD 14.91 billion by 2030.

Oncology biosimilars are biologic medical products highly similar to already approved reference biologics, playing a crucial role in cancer treatment by providing more affordable options. These biosimilars are developed to match their reference counterparts in terms of safety, purity, and efficacy, offering significant cost savings for healthcare systems and patients. The necessity for oncology biosimilars emerges from the growing global incidence of cancer and the unsustainable costs associated with biologic treatments. They find application across a wide range of oncological therapies including monoclonal antibodies and adjunctive therapies, with primary end-users being hospitals, clinics, and cancer treatment centers. Market growth is driven by patent expirations of blockbuster biologics, increasing pressure to reduce healthcare expenditures, and advancements in biotechnology that streamline biosimilar production. Potential opportunities lie in untapped markets in emerging economies, which are seeking cost-effective cancer treatments, and the continuous patent expiration of original biologics. Companies can capitalize on these by investing in robust R&D and strategic partnerships, ensuring competitive pricing, and navigating regulatory pathways effectively. However, market growth faces challenges such as stringent regulatory requirements, high development costs, physician/patient skepticism, and issues related to biosimilar interchangeability and substitution. The best areas for innovation and research include improving the manufacturing processes to increase yield and reduce cost, enhancing delivery systems for better patient compliance, and developing differentiation strategies to distinguish in the competitive landscape. The market is characterized by high competition and rapid technological advancements, with a strong focus on evidence-based outcomes to demonstrate efficacy and safety. Companies must strategically leverage technological innovations, engage in active stakeholder education, and optimize supply chain dynamics to sustain growth and broaden their footprint in the oncology biosimilars market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Biosimilars Market

The Oncology Biosimilars Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rapid approval by regulatory authorities for commercialization of products
  • Rising incidence of various types of cancers and leukemia
  • Recent innovation in clinical drug development
• Market Restraints
  • High costs involved in the research
• Market Opportunities
  • Introduction of new and innovative treatment options
  • Strategic alliances and investment for capacity expansion
• Market Challenges
  • Limited clinical safety and efficacy data

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Biosimilars Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Biosimilars Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Biosimilars Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Biosimilars Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Biosimilars Market

A detailed market share analysis in the Oncology Biosimilars Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Biosimilars Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Biosimilars Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Biosimilars Market

A strategic analysis of the Oncology Biosimilars Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Allergan plc, Amneal Pharmaceuticals LLC., Apotex Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, Endo International plc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, JSC BIOCAD, Lupin Limited, Mylan N.V., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Oncology Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Application, market is studied across Cancer Treatment Drugs and Supportive Care Drugs.
• Based on End-User, market is studied across Hospitals and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rapid approval by regulatory authorities for commercialization of products
    • 5.1.1.2. Rising incidence of various types of cancers and leukemia
    • 5.1.1.3. Recent innovation in clinical drug development
  • 5.1.2. Restraints
    • 5.1.2.1. High costs involved in the research
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of new and innovative treatment options
    • 5.1.3.2. Strategic alliances and investment for capacity expansion
  • 5.1.4. Challenges
    • 5.1.4.1. Limited clinical safety and efficacy data
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncology Biosimilars Market, by Application

• 6.1. Introduction
• 6.2. Cancer Treatment Drugs
• 6.3. Supportive Care Drugs

7. Oncology Biosimilars Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Retail Pharmacies

8. Americas Oncology Biosimilars Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Oncology Biosimilars Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Oncology Biosimilars Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Allergan plc
• 2. Amneal Pharmaceuticals LLC.
• 3. Apotex Inc.
• 4. Aurobindo Pharma Limited
• 5. Bristol-Myers Squibb Company
• 6. Cipla Inc.
• 7. Eli Lilly and Company
• 8. Endo International plc
• 9. F. Hoffmann-La Roche Ltd.
• 10. GlaxoSmithKline plc
• 11. Glenmark Pharmaceuticals Limited
• 12. JSC BIOCAD
• 13. Lupin Limited
• 14. Mylan N.V.
• 15. Novartis AG